SpyGlass Pharma, Inc. (SGP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SpyGlass Pharma, Inc. (SGP) has a cash flow conversion efficiency ratio of -0.064x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.84 Million) by net assets ($232.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SGP market cap overview for the company's overall valuation and market capitalisation.
SpyGlass Pharma, Inc. - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how SpyGlass Pharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for SpyGlass Pharma, Inc. for real-time trading data and today's change.
SpyGlass Pharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SpyGlass Pharma, Inc. ranked by their cash flow conversion efficiency. Review SpyGlass Pharma, Inc. (SGP) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Huachang Chemical Co Ltd
SHE:002274
|
0.011x |
|
Shanghai Ganglian E Commerce
SHE:300226
|
0.033x |
|
Si-Bone Inc
NASDAQ:SIBN
|
0.004x |
|
Embracer Group AB Series B
LSE:0GFE
|
0.075x |
|
Logwin AG
XETRA:TGHN
|
0.123x |
|
Shandong Jinjing Science and Technology Stock Co Ltd
SHG:600586
|
-0.032x |
|
Capital City Bank Group
NASDAQ:CCBG
|
0.022x |
|
Decai Decoration Co Ltd
SHG:605287
|
0.009x |
Annual Cash Flow Conversion Efficiency for SpyGlass Pharma, Inc. (2023–2025)
The table below shows the annual cash flow conversion efficiency of SpyGlass Pharma, Inc. from 2023 to 2025. Also see SGP total asset value for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-98.84 Million | $-32.70 Million | 0.331x | -9.16% |
| 2024-12-31 | $-60.47 Million | $-22.03 Million | 0.364x | -2.14% |
| 2023-12-31 | $-32.99 Million | $-12.28 Million | 0.372x | -- |
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intra… Read more